Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
Flora Pirozzi, Remo Poto, Luisa Aran, et al.
Current Oncology Reports (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 203
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 949-982
Open Access | Times Cited: 168
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Walid Shalata, Amjad Abu-Salman, Rachel Steckbeck, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5218-5218
Open Access | Times Cited: 85
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
Annamaria Mascolo, Cristina Scavone, Carmen Ferrajolo, et al.
Drug Safety (2021) Vol. 44, Iss. 9, pp. 957-971
Open Access | Times Cited: 61
Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor–induced Myocarditis
Farah Cadour, Jennifer Cautela, Stanislas Rapacchi, et al.
Radiology (2022) Vol. 303, Iss. 3, pp. 512-521
Open Access | Times Cited: 50
Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology
Carlo G. Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2055-2076
Closed Access | Times Cited: 13
A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients
Chin-Chin Ho, Shang-Liang Wu, Han‐Yi Tsai, et al.
Journal of the Chinese Medical Association (2023) Vol. 86, Iss. 5, pp. 499-505
Open Access | Times Cited: 16
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors
Walid Shalata, Sarah Weissmann, Sapir Itzhaki Gabay, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5451-5451
Open Access | Times Cited: 23
Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy
Charlotte Lee, Zsófia D. Drobni, Amna Zafar, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 660-669
Open Access | Times Cited: 22
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
Ting Yan, Minghui Long, Chaoyi Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy
Danielle Delombaerde, Delphine Vervloet, Constantijn Franssen, et al.
ESMO Open (2021) Vol. 6, Iss. 4, pp. 100216-100216
Open Access | Times Cited: 28
Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?
Nathan Karin
Cancers (2021) Vol. 13, Iss. 24, pp. 6317-6317
Open Access | Times Cited: 27
Cancer immunotherapy and the management of side effects
Preethika Mahalingam, Thomas Newsom-Davis
Clinical Medicine (2023) Vol. 23, Iss. 1, pp. 56-60
Open Access | Times Cited: 12
Advances in immune checkpoint inhibitors induced-cardiotoxicity
Xiang Li, Wenying Peng, Jiao Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Impact of baseline glucocorticoids (GCs) on cardiotoxic events and myocardial damage related to immune checkpoint inhibitors: a retrospective clinical research
Qiaoyun Wang, Haixia Zhang, Yawen Chen, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Pembrolizumab associated hypereosinophilia in locally advanced triple-negative breast cancer
Remo Poto, Antonio Di Salvatore, Laura Stigliano, et al.
Exploration of Medicine (2025)
Open Access
The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure
Song Huang, Yu Kang, Ting Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Multifunctional role of nanoparticles for the diagnosis and therapeutics of cardiovascular diseases
Ihtesham Arshad, Ayesha Kanwal, Imran Zafar, et al.
Environmental Research (2023) Vol. 242, pp. 117795-117795
Closed Access | Times Cited: 10
Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology
Yingying He, Hui Yu, Shuang Dai, et al.
Genes & Diseases (2023) Vol. 11, Iss. 2, pp. 807-818
Open Access | Times Cited: 9
Immune Checkpoint Inhibitor-Associated Myocarditis: From Pathophysiology to Rechallenge of Therapy – a Narrative Review
Andrea Tedeschi, Massimiliano Camilli, Enrico Ammirati, et al.
Future Cardiology (2023) Vol. 19, Iss. 2, pp. 91-103
Closed Access | Times Cited: 9
Nano revolution in cardiovascular health: Nanoparticles (NPs) as tiny titans for diagnosis and therapeutics
Junaid Abid, Fatma Mohamed Ameen Khalil, Sumbul Saeed, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 5, pp. 102466-102466
Closed Access | Times Cited: 3
Genetic factors in the pathogenesis of cardio-oncology
Yalong Qi, Yuhan Wei, Lixi Li, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis
Alexi Vasbinder, Anis Ismail, Joe‐Elie Salem, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 9, pp. 959-967
Closed Access | Times Cited: 8
Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience
Junjuan Xiao, Xingyu Li, Xuan Wang, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 7
Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System
Stefan Milutinovic, Predrag Jancic, Vera Jokić, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1372-1372
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top